# Olaf StÃ¼ve

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2619292/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 181 papers | 12,552 citations | 28274 55 h-index | 25787 108 g-index |
| 186 all docs | 186 docs citations | 186 times ranked | 12103 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286. | 1.1 | 2,344 |
| 2 | The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature, 2002, 420, 78-84. | 27.8 | 1,060 |
| 3 | Immune surveillance in multiple sclerosis patients treated with natalizumab. Annals of Neurology, 2006, 59, 743-747. | 5.3 | 414 |
| 4 | Type II monocytes modulate T cellâ€“mediated central nervous system autoimmune disease. Nature Medicine, 2007, 13, 935-943. | 30.7 | 407 |
| 5 | The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal, 2015, 21, 305-317. | 3.0 | 381 |
| 6 | Interferon beta in the treatment of multiple sclerosis. Neurology, 1998, 51, 682-689. | 1.1 | 344 |
| 7 | Interferon Î²-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9. Annals of Neurology, 1996, 40, 853-863. | 5.3 | 338 |
| 8 | A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Multiple Sclerosis Journal, 2015, 21, 263-281. | 3.0 | 273 |
| 9 | Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. Archives of Neurology, 2006, 63, 1383. | 4.5 | 271 |
| 10 | Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurology, The, 2013, 12, 756-767. | 10.2 | 205 |
| 11 | The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nature Reviews Neurology, 2013, 9, 267-276. | 10.1 | 181 |
| 12 | Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab. Archives of Neurology, 2008, 65, 1596. | 4.5 | 179 |
| 13 | The increasing incidence and prevalence of female multiple sclerosisâ€”A critical analysis of potential environmental factors. Autoimmunity Reviews, 2011, 10, 495-502. | 5.8 | 174 |
| 14 | Optical coherence tomography in multiple sclerosis. Lancet Neurology, The, 2006, 5, 853-863. | 10.2 | 165 |
| 15 | High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS). JAMA Neurology, 2015, 72, 159. | 9.0 | 158 |
| 16 | Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796. | 7.6 | 139 |
| 17 | B lymphocytes in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e104. | 6.0 | 132 |
| 18 | A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 282-293. | 3.0 | 131 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 318-331. | 3.0 | 131 |
| 20 | Plasma Exchange in Neuroimmunological Disorders. Archives of Neurology, 2006, 63, 930. | 4.5 | 130 |
| 21 | Clinical Stabilization and Effective B-Lymphocyte Depletion in the Cerebrospinal Fluid and Peripheral Blood of a Patient With Fulminant Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2005, 62, 1620-3. | 4.5 | 124 |
| 22 | Immunological Aspects of Approved MS Therapeutics. Frontiers in Immunology, 2019, 10, 1564. | 4.8 | 117 |
| 23 | Memory B cells from a subset of treatmentâ€naÃ¯ve relapsingâ€remitting multiple sclerosis patients elicit CD4<sup>+</sup> Tâ€cell proliferation and IFNâ€Î³ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. European Journal of Immunology, 2010, 40, 2942-2956. | 2.9 | 114 |
| 24 | Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica. JAMA Neurology, 2013, 70, 390. | 9.0 | 112 |
| 25 | Natalizumab and Progressive Multifocal Leukoencephalopathy. Archives of Neurology, 2010, 67, 923-30. | 4.5 | 105 |
| 26 | Statins â€" a cure-all for the brain?. Nature Reviews Neuroscience, 2005, 6, 325-331. | 10.2 | 104 |
| 27 | Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. Journal of Neuroimmunology, 1997, 80, 38-46. | 2.3 | 102 |
| 28 | A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 342-349. | 3.0 | 100 |
| 29 | Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (TysabriÂ®) in Inflammatory Diseases. CNS Neuroscience & Therapeutics, 2007, 13, 79-95. | 4.0 | 98 |
| 30 | Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. Journal of Clinical Investigation, 2006, 116, 1037-1044. | 8.2 | 98 |
| 31 | Statins as potential therapeutic agents in neuroinflammatory disorders. Current Opinion in Neurology, 2003, 16, 393-401. | 3.6 | 97 |
| 32 | Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2016, 73, 1089. | 9.0 | 92 |
| 33 | The Role of the MHC Class II Transactivator in Class II Expression and Antigen Presentation by Astrocytes and in Susceptibility to Central Nervous System Autoimmune Disease. Journal of Immunology, 2002, 169, 6720-6732. | 0.8 | 83 |
| 34 | Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. Journal of Neuroimmunology, 2010, 219, 1-7. | 2.3 | 82 |
| 35 | A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 294-304. | 3.0 | 79 |
| 36 | Statins as potential therapeutic agents in neuroinflammatory disorders. Current Opinion in Neurology, 2003, 16, 393-401. | 3.6 | 78 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Primary central nervous system lymphoma in a patient treated with natalizumab. Annals of Neurology, 2009, 66, 403-406. | 5.3 | 78 |
| 38 | Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity. Journal of Clinical Investigation, 2001, 108, 1133-1139. | 8.2 | 78 |
| 39 | Are statins a treatment option for multiple sclerosis?. Lancet Neurology, The, 2004, 3, 369-371. | 10.2 | 77 |
| 40 | Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurology, The, 2005, 4, 403-412. | 10.2 | 77 |
| 41 | Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641985498. | 3.5 | 76 |
| 42 | Î±4-Integrin antagonism with natalizumab. Journal of Neurology, 2008, 255, 58-65. | 3.6 | 74 |
| 43 | Plasma Exchange in Neuroimmunological Disorders. Archives of Neurology, 2006, 63, 1066. | 4.5 | 71 |
| 44 | Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurology, The, 2008, 7, 173-183. | 10.2 | 70 |
| 45 | Rituximab Therapy Reduces Organ-Specific T Cell Responses and Ameliorates Experimental Autoimmune Encephalomyelitis. PLoS ONE, 2011, 6, e17103. | 2.5 | 69 |
| 46 | Dimethyl fumarate in relapsingâ€“remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Review of Neurotherapeutics, 2015, 15, 339-346. | 2.8 | 69 |
| 47 | Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis. Neurotherapeutics, 2016, 13, 58-69. | 4.4 | 69 |
| 48 | B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641876169. | 3.5 | 67 |
| 49 | Migratory behavior of lymphocytes isolated from multiple sclerosis patients: Effects of interferon ?-1b therapy. Annals of Neurology, 1999, 46, 319-324. | 5.3 | 66 |
| 50 | Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy. Archives of Neurology, 2007, 64, 169. | 4.5 | 65 |
| 51 | A critical appraisal of treatment decisions in multiple sclerosisâ€”old versus new. Nature Reviews Neurology, 2011, 7, 255-262. | 10.1 | 64 |
| 52 | Disease-Modifying Agents for Multiple Sclerosis. Drugs, 2008, 68, 2445-2468. | 10.9 | 63 |
| 53 | Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. Journal of Neuroimmunology, 2005, 168, 128-137. | 2.3 | 60 |
| 54 | Statins in the treatment of central nervous system autoimmune disease. Journal of Neuroimmunology, 2006, 178, 140-148. | 2.3 | 59 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2015, 72, 815. | 9.0 | 59 |
| 56 | Review: Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Therapeutic Advances in Neurological Disorders, 2009, 2, 357-368. | 3.5 | 57 |
| 57 | Multiple Sclerosis in the Elderly Patient. Drugs and Aging, 2010, 27, 283-294. | 2.7 | 55 |
| 58 | Immunopathogenesis of Neuromyelitis Optica. Advances in Immunology, 2014, 121, 213-242. | 2.2 | 55 |
| 59 | Immunophenotyping of Cerebrospinal Fluid Cells in Multiple Sclerosis. JAMA Neurology, 2014, 71, 905. | 9.0 | 54 |
| 60 | Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?. Multiple Sclerosis Journal, 2014, 20, 1304-1305. | 3.0 | 53 |
| 61 | Corticosteroids for Multiple Sclerosis: I. Application for Treating Exacerbations. Neurotherapeutics, 2007, 4, 618-626. | 4.4 | 52 |
| 62 | Alemtuzumab. Neurology, 2014, 83, 87-97. | 1.1 | 52 |
| 63 | Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients. PLoS ONE, 2008, 3, e2028. | 2.5 | 51 |
| 64 | Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project. Journal of the American College of Radiology, 2017, 14, 371-379.e1. | 1.8 | 49 |
| 65 | Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects. Current Pharmaceutical Design, 2012, 18, 209-219. | 1.9 | 48 |
| 66 | Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices. Current Neuropharmacology, 2011, 9, 417-428. | 2.9 | 47 |
| 67 | Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-Î³-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4+T-cell activation. Glia, 2001, 36, 391-405. | 4.9 | 46 |
| 68 | The spectrum of autoimmune encephalopathies. Journal of Neuroimmunology, 2015, 287, 93-97. | 2.3 | 46 |
| 69 | Inhibition by Mitoxantrone of In Vitro Migration of Immunocompetent Cells. Archives of Neurology, 2006, 63, 1572. | 4.5 | 43 |
| 70 | Pharmacological Treatment of Early Multiple Sclerosis. Drugs, 2008, 68, 73-83. | 10.9 | 41 |
| 71 | The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 876-886. | 3.0 | 41 |
| 72 | PEG Minocycline-Liposomes Ameliorate CNS Autoimmune Disease. PLoS ONE, 2009, 4, e4151. | 2.5 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal, 2015, 21, 332-341. | 3.0 | 39 |
| 74 | Evolution of clinical trials in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641982654. | 3.5 | 37 |
| 75 | The effects of natalizumab on the innate and adaptive immune system in the central nervous system. Journal of the Neurological Sciences, 2008, 274, 39-41. | 0.6 | 36 |
| 76 | Choroid plexus volumetrics and brain inflammation in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 7.1 | 34 |
| 77 | Lymph node-derived donor encephalitogenic CD4+T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet. Journal of Neuroinflammation, 2011, 8, 73. | 7.2 | 33 |
| 78 | Immune surveillance of the central nervous system in multiple sclerosis â€" Relevance for therapy and experimental models. Journal of Neuroimmunology, 2014, 276, 9-17. | 2.3 | 30 |
| 79 | B cell-directed therapies in multiple sclerosis. Neurodegenerative Disease Management, 2016, 6, 37-47. | 2.2 | 30 |
| 80 | A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2010, 3, 15-28. | 3.5 | 29 |
| 81 | Diagnostic and therapeutic strategies for management of autoimmune encephalopathies. Expert Review of Neurotherapeutics, 2016, 16, 937-949. | 2.8 | 29 |
| 82 | The role of B cells in multiple sclerosis: Current and future therapies. Cellular Immunology, 2019, 339, 10-23. | 3.0 | 29 |
| 83 | Immunomodulatory treatment strategies in multiple sclerosis. Journal of Neurology, 2008, 255, 15-21. | 3.6 | 27 |
| 84 | Diclofenac reduces the risk of Alzheimerâ€™s disease: a pilot analysis of NSAIDs in two US veteran populations. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093567. | 3.5 | 27 |
| 85 | The Combination of Interferonâ€Beta and HMGâ€CoA Reductase Inhibition in Multiple Sclerosis: Enthusiasm Lost too Soon?. CNS Neuroscience and Therapeutics, 2010, 16, 362-373. | 3.9 | 26 |
| 86 | Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database. Multiple Sclerosis Journal, 2021, 27, 1066-1076. | 3.0 | 26 |
| 87 | Para-dichlorobenzene toxicity â€" a review of potential neurotoxic manifestations. Therapeutic Advances in Neurological Disorders, 2014, 7, 177-187. | 3.5 | 25 |
| 88 | Management of Secondary Progressive Multiple Sclerosis: Prophylactic Treatmentâ€"Past, Present, and Future Aspects. Current Treatment Options in Neurology, 2013, 15, 241-258. | 1.8 | 24 |
| 89 | Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating Î²7+ T Cells in Crohnâ€™s Disease: Report of the TOSCA Study. Journal of Crohn's and Colitis, 2018, 12, 188-196. | 1.3 | 24 |
| 90 | Similar Biophysical Abnormalities in Glomeruli and Podocytes from Two Distinct Models. Journal of the American Society of Nephrology: JASN, 2018, 29, 1501-1512. | 6.1 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Central nervous system infections â€“ a potential complication of systemic immunotherapy. Current Opinion in Neurology, 2006, 19, 271-276. | 3.6 | 22 |
| 92 | CD19 as a molecular target in CNS autoimmunity. Acta Neuropathologica, 2014, 128, 177-190. | 7.7 | 22 |
| 93 | Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?. Frontiers in Neurology, 2020, 11, 607766. | 2.4 | 22 |
| 94 | A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. Multiple Sclerosis Journal, 2013, 19, 59-68. | 3.0 | 21 |
| 95 | Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology. Journal of Immunology, 2017, 198, 1381-1386. | 0.8 | 21 |
| 96 | Statins and their potential targets in multiple sclerosis therapy. Expert Opinion on Therapeutic Targets, 2003, 7, 613-622. | 3.4 | 20 |
| 97 | Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642096901. | 3.5 | 20 |
| 98 | Direct and consensual murine pupillary reflex metrics: Establishing normative values. Autonomic Neuroscience: Basic and Clinical, 2009, 151, 164-167. | 2.8 | 19 |
| 99 | Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, S58-S61. | 3.0 | 18 |
| 100 | Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity. European Journal of Immunology, 2013, 43, 2078-2088. | 2.9 | 18 |
| 101 | Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis â€“ an observational study. European Journal of Clinical Investigation, 2015, 45, 587-593. | 3.4 | 17 |
| 102 | Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics, 2016, 16, 1131-1139. | 2.8 | 17 |
| 103 | MAdCAM-1-Mediated Intestinal Lymphocyte Homing Is Critical for the Development of Active Experimental Autoimmune Encephalomyelitis. Frontiers in Immunology, 2019, 10, 903. | 4.8 | 17 |
| 104 | Therapeutic Potential of Small Interfering RNA for Central Nervous System Diseases. Archives of Neurology, 2005, 62, 1810. | 4.5 | 16 |
| 105 | Human Aquaporin 4<sub>281-300</sub>Is the Immunodominant Linear Determinant in the Context of HLA-DRB1*03:01. Archives of Neurology, 2012, 69, 1125-31. | 4.5 | 16 |
| 106 | Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. Expert Review of Clinical Immunology, 2015, 11, 93-108. | 3.0 | 16 |
| 107 | Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis. Current Opinion in Neurology, 2016, 29, 278-285. | 3.6 | 16 |
| 108 | Neurofilament light chain. Neurology, 2019, 92, 451-452. | 1.1 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients. PLoS ONE, 2020, 15, e0228617. | 2.5 | 16 |
| 110 | Approved and Future Pharmacotherapy for Multiple Sclerosis. Neurologist, 2002, 8, 290-301. | 0.7 | 15 |
| 111 | Knowns and unknowns in the future of multiple sclerosis treatment. Journal of the Neurological Sciences, 2009, 287, S30-S36. | 0.6 | 14 |
| 112 | Reelin depletion protects against autoimmune encephalomyelitis by decreasing vascular adhesion of leukocytes. Science Translational Medicine, 2020, 12, . | 12.4 | 14 |
| 113 | The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. Journal of Neuroinflammation, 2013, 10, 67. | 7.2 | 12 |
| 114 | Primary progressive multiple sclerosisâ€"why we are failing. Lancet, The, 2016, 387, 1032-1034. | 13.7 | 12 |
| 115 | Multiple sclerosis therapy: An update on recently finished trials. Journal of Neurology, 2007, 254, 1473-1490. | 3.6 | 11 |
| 116 | DNA-based vaccines: the future of multiple sclerosis therapy?. Expert Review of Neurotherapeutics, 2008, 8, 351-360. | 2.8 | 11 |
| 117 | Translational Research in Neurology and Neuroscience 2010. Archives of Neurology, 2010, 67, 1307-15. | 4.5 | 11 |
| 118 | Natalizumab: Perspectives from the Bench to Bedside. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a029066. | 6.2 | 11 |
| 119 | Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e437. | 6.0 | 11 |
| 120 | CD11c<sup>+</sup>CD88<sup>+</sup>CD317<sup>+</sup>myeloid cells are critical mediators of persistent CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 7.1 | 11 |
| 121 | Disease-modifying therapy prescription patterns in people with multiple sclerosis by age. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110064. | 3.5 | 11 |
| 122 | Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab. Neuropsychiatric Disease and Treatment, 2015, 11, 2405. | 2.2 | 10 |
| 123 | B-cellâ€"targeted therapies in relapsing forms of MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e405. | 6.0 | 10 |
| 124 | Emerging drugs for primary progressive multiple sclerosis. Expert Opinion on Emerging Drugs, 2018, 23, 97-110. | 2.4 | 10 |
| 125 | Clinical trials in multiple sclerosis: potential future trial designs. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984709. | 3.5 | 10 |
| 126 | Î±4-integrin deficiency in B cells does not affect disease in a T-cellâ€"mediated EAE disease model. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e563. | 6.0 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure. Frontiers in Neurology, 2022, 13, 854390. | 2.4 | 9 |
| 128 | Multiple Sclerosis Disease Progression and Paradichlorobenzene. JAMA Neurology, 2014, 71, 228. | 9.0 | 8 |
| 129 | Managing Disability in Progressive Multiple Sclerosis. Current Treatment Options in Neurology, 2016, 18, 27. | 1.8 | 8 |
| 130 | <scp>TLR</scp>3 agonism reâ€establishes <scp>CNS</scp> immune competence during Î±4â€integrin deficiency. Annals of Clinical and Translational Neurology, 2018, 5, 1543-1561. | 3.7 | 8 |
| 131 | Simplification of combination antiretroviral therapy (cART) and the brainâ€”a real-life experience. Journal of NeuroVirology, 2019, 25, 174-182. | 2.1 | 8 |
| 132 | Apolipoprotein E receptor 2 deficiency decreases endothelial adhesion of monocytes and protects against autoimmune encephalomyelitis. Science Immunology, 2021, 6, . | 11.9 | 8 |
| 133 | Revised criteria for neuromyelitis opticaâ€”a new diagnostic standard?. Nature Clinical Practice Neurology, 2007, 3, 132-133. | 2.5 | 7 |
| 134 | Isoniazid in autoimmunity: a trigger for multiple sclerosis?. Therapeutic Advances in Neurological Disorders, 2014, 7, 253-256. | 3.5 | 7 |
| 135 | Natalizumab to fingolimodâ€”the washout whitewash. Nature Reviews Neurology, 2014, 10, 311-313. | 10.1 | 7 |
| 136 | Clinical trials in multiple sclerosis: milestones. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878549. | 3.5 | 7 |
| 137 | Trials and therapies in secondary progressive MS, simplified. Nature Reviews Neurology, 2019, 15, 431-432. | 10.1 | 7 |
| 138 | A Single Amino Acid Substitution Prevents Recognition of a Dominant Human Aquaporin-4 Determinant in the Context of HLA-DRB1*03:01 by a Murine TCR. PLoS ONE, 2016, 11, e0152720. | 2.5 | 7 |
| 139 | IL-12/IL-23p40 Is Highly Expressed in Secondary Lymphoid Organs and the CNS during All Stages of EAE, but Its Deletion Does Not Affect Disease Perpetuation. PLoS ONE, 2016, 11, e0165248. | 2.5 | 7 |
| 140 | Anticipated benefits and surprising effects of daclizumab in multiple sclerosis. Lancet Neurology, The, 2010, 9, 337-338. | 10.2 | 6 |
| 141 | From injection therapies to natalizumab: views on the treatment of multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2012, 5, 97-104. | 3.5 | 6 |
| 142 | Acute relapse after initiation of Siponimod in a patient with secondary progressive MS. Journal of Neurology, 2016, 263, 606-610. | 3.6 | 6 |
| 143 | Persistent severe lymphopenia 5â€‰years after dimethyl fumarate discontinuation. Multiple Sclerosis Journal, 2021, 27, 1306-1308. | 3.0 | 6 |
| 144 | Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease. Journal of Neuroimmunology, 2017, 309, 100-110. | 2.3 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Limitations of cell-lineage-specific non-dynamic gene recombination in CD11c.Cre+ITGA4fl/fl mice. Journal of Neuroimmunology, 2020, 344, 577245. | 2.3 | 5 |
| 146 | Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199050. | 3.5 | 5 |
| 147 | Genetic Polymorphism at Codon 129 of the Prion Protein Gene Is Not Associated With Multiple Sclerosis. Archives of Neurology, 2009, 66, 280-1. | 4.5 | 4 |
| 148 | Firategrastâ€"natalizumab in a pill?. Lancet Neurology, The, 2012, 11, 120-121. | 10.2 | 4 |
| 149 | Multiple sclerosis drugs: how much bang for the buck?. Lancet Neurology, The, 2015, 14, 460-461. | 10.2 | 4 |
| 150 | Will Biomarkers Determine What Is Next in Multiple Sclerosis?. JAMA Neurology, 2016, 73, 496. | 9.0 | 4 |
| 151 | Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitis. PLoS ONE, 2018, 13, e0200752. | 2.5 | 4 |
| 152 | A bird's-eye view of T cells during natalizumab therapy. Neurology, 2013, 81, 1372-1373. | 1.1 | 3 |
| 153 | Does Natalizumab Therapy Benefit Patients With Multiple Sclerosis?. JAMA Neurology, 2014, 71, 945. | 9.0 | 3 |
| 154 | Treatment Decisions for Patients With Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 387. | 9.0 | 3 |
| 155 | High Incidence of Postâ€"Lumbar Puncture Headaches in Patients With Multiple Sclerosis Treated With Natalizumab: Role of Intrathecal Leukocytes. Archives of Neurology, 2007, 64, 1055. | 4.5 | 2 |
| 156 | Natalizumab: increased vigilance is required in treating patients with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2008, 1, 155-156. | 3.5 | 2 |
| 157 | Progressive multiple sclerosis: desperately seeking remedy. Lancet Neurology, The, 2013, 12, 840-841. | 10.2 | 2 |
| 158 | The genetics of natalizumab hypersensitivity. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e52. | 6.0 | 2 |
| 159 | Natalizumab to fingolimod. Neurology, 2015, 85, 14-15. | 1.1 | 2 |
| 160 | Spotlight on daclizumab: its potential in the treatment of multiple sclerosis. Degenerative Neurological and Neuromuscular Disease, 2016, Volume 6, 95-109. | 1.3 | 2 |
| 161 | Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of â€˜Chinese restaurant syndromeâ€™. Journal of Neurology, 2016, 263, 1027-1028. | 3.6 | 2 |
| 162 | Natalizumab wearing-off effect. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e706. | 6.0 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Systems Approaches to Unravel T Cell Function and Therapeutic Potential in Autoimmune Disease. Journal of Immunology, 2021, 206, 669-675. | 0.8 | 2 |
| 164 | Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: Early Results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI). Blood, 2011, 118, 3075-3075. | 1.4 | 2 |
| 165 | Biological Significance of Antiâ€“SARS-CoV-2 Antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, . | 6.0 | 2 |
| 166 | Cognitive Decline in Older People with Multiple Sclerosisâ€”A Narrative Review of the Literature. Geriatrics (Switzerland), 2022, 7, 61. | 1.7 | 2 |
| 167 | Is 1+1 0, 1, 2, or 11? Arithmetics of antiinflammatory agents in autoimmunity. Experimental Neurology, 2009, 217, 4-6. | 4.1 | 1 |
| 168 | Heat exposure and bicycling trigger recurrent aseptic meningitis: a case report. BMC Neurology, 2014, 14, 230. | 1.8 | 1 |
| 169 | The major histocompatibility complex and antibodyâ€mediated limbic encephalitis. Annals of Neurology, 2017, 81, 181-182. | 5.3 | 1 |
| 170 | Normal intrathecal leukocyte cell number and composition do not decrease the incidence of postâ€“lumbar puncture headache. Journal of Neuroimmunology, 2017, 310, 69-71. | 2.3 | 1 |
| 171 | PDCB does not promote CNS autoimmunity in the context of genetic susceptibility but worsens its outcome. Journal of Neuroimmunology, 2018, 323, 53-55. | 2.3 | 1 |
| 172 | Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report. Journal of Central Nervous System Disease, 2021, 13, 117957352110537. | 1.9 | 1 |
| 173 | To the editors: Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England. Multiple Sclerosis and Related Disorders, 2022, 59, 103541. | 2.0 | 1 |
| 174 | Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance. Journal of Neuroimmunology, 2014, 276, 232-235. | 2.3 | 0 |
| 175 | Smoking Beyond Multiple Sclerosis Diagnosis. JAMA Neurology, 2015, 72, 1105. | 9.0 | 0 |
| 176 | Targeting â€œbadâ€•B cells in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e283. | 6.0 | 0 |
| 177 | WED 183â€…Cladribine tablets effects on t cell subsets in patients with early ms. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A25.2-A25. | 1.9 | 0 |
| 178 | WED 186â€…Effect of cladribine tablets on immune cells in patients with ms. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A26.2-A26. | 1.9 | 0 |
| 179 | The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo. Journal of Neuroimmunology, 2021, 354, 577544. | 2.3 | 0 |
| 180 | Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: 2-Year Follow-up Results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI). Blood, 2012, 120, 962-962. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Utilization of a neurology specialty service by primary care providers for headache management at a tertiary care hospital. Journal of Central Nervous System Disease, 2022, 14, 117957352211131. | 1.9 | 0 |